Midyear Review from the Cancer Vaccine Institute

The first half of 2026 has been an exciting one at the Cancer Vaccine Institute (CVI), and we are proud to share the progress we’ve made in our Midyear Review.

We have six clinical trials actively recruiting, with four additional studies opening soon. Our faculty and research teams have been recognized through competitive awards, invited presentations, and impactful scientific publications. These achievements highlight the significance of our work and elevate the visibility of cancer vaccine research. We are growing our team to support these advances and to accelerate the delivery of vaccines to patients.

Thank you to our patients, faculty, staff, trainees, and collaborators whose commitment makes this progress possible. We hope this Midyear Review offers both a meaningful reflection on our recent accomplishments and an inspiring glimpse of the work ahead.

Explore our Midyear Review here. Stay connected with the latest by subscribing to our newsletter and following us on social media for research highlights, clinical trial updates, events, and more throughout the year.